FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945640033> ?p ?o ?g. }

• W2945640033 endingPage "1141" @default.
• W2945640033 startingPage "1132" @default.
• W2945640033 abstract "Background: Extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) is increasing worldwide. The drugs of choice for treatment of ESBLs are parenteral carbapenems. The aim of this study was to evaluate the in vitro and in vivo efficacy of a new combination of oral cephalosporins and amoxicillin/clavulanate in treatment of ESBL-EC. Methods: A total of 150 ESBL-EC samples were collected over 1 year from two referral centers. Synergistic studies of cephalosporins and amoxicillin/clavulanate were performed in vitro using disk approximation and disk replacement methods. Combination treatment was assessed in vivo on 20 ESBL-EC urinary tract infection (UTI) patients. Results: ESBL-EC isolates were confirmed in 150 patients with a mean age of 46.67 years, 75.2% of them being women. Antibiotic susceptibility testing of isolates indicated high resistance rate to oral antibiotics. The frequency of positive synergy and mean distance of synergy between cephalosporins and amoxicillin/clavulanate was significantly higher with cefotaxime and cefixime compared with cefpodoxime, cefdinir, and ceftazidime using disk approximation and disk replacement methods (p < 0.05). Addition of amoxicillin/clavulanate enhanced the susceptibility rate with cefixime from 8.6% to 86.3%, significantly higher than with other cephalosporins (p < 0.0005). Cefixime and amoxicillin/clavulanate synergy was not affected by age, gender, hospital, department, sample type, or bacterial load. Eighteen of 20 ESBL-EC-positive UTI patients had a positive in vitro synergy test and complete clinical and microbiological resolution after completion of cefixime and amoxicillin/clavulanate oral treatment course. Conclusions: Cefixime and amoxicillin/clavulanate combination therapy could be an effective oral outpatient treatment option for ESBL-EC. In vitro synergistic testing is simple and predictive of successful treatment." @default.
• W2945640033 created "2019-05-29" @default.
• W2945640033 creator A5000218370 @default.
• W2945640033 creator A5024136656 @default.
• W2945640033 creator A5027889441 @default.
• W2945640033 creator A5051915095 @default.
• W2945640033 creator A5077536735 @default.
• W2945640033 date "2019-10-01" @default.
• W2945640033 modified "2023-09-27" @default.
• W2945640033 title "Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing<i>Escherichia coli</i>" @default.
• W2945640033 cites W1240542110 @default.
• W2945640033 cites W1489239813 @default.
• W2945640033 cites W1837797665 @default.
• W2945640033 cites W1907889903 @default.
• W2945640033 cites W1924728346 @default.
• W2945640033 cites W1964107212 @default.
• W2945640033 cites W1987935724 @default.
• W2945640033 cites W2005878220 @default.
• W2945640033 cites W2007707957 @default.
• W2945640033 cites W2009786282 @default.
• W2945640033 cites W2018438682 @default.
• W2945640033 cites W2025455884 @default.
• W2945640033 cites W2040129835 @default.
• W2945640033 cites W2049137567 @default.
• W2945640033 cites W2065337857 @default.
• W2945640033 cites W2095140111 @default.
• W2945640033 cites W2097094769 @default.
• W2945640033 cites W2121254474 @default.
• W2945640033 cites W2128172436 @default.
• W2945640033 cites W2131946678 @default.
• W2945640033 cites W2136572748 @default.
• W2945640033 cites W2137134680 @default.
• W2945640033 cites W2144881710 @default.
• W2945640033 cites W2328244885 @default.
• W2945640033 cites W2440223497 @default.
• W2945640033 cites W2528299860 @default.
• W2945640033 cites W2778650888 @default.
• W2945640033 cites W2786886659 @default.
• W2945640033 cites W4241111610 @default.
• W2945640033 cites W2122821975 @default.
• W2945640033 doi "https://doi.org/10.1089/mdr.2019.0065" @default.
• W2945640033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31107146" @default.
• W2945640033 hasPublicationYear "2019" @default.
• W2945640033 type Work @default.
• W2945640033 sameAs 2945640033 @default.
• W2945640033 citedByCount "22" @default.
• W2945640033 countsByYear W29456400332020 @default.
• W2945640033 countsByYear W29456400332021 @default.
• W2945640033 countsByYear W29456400332022 @default.
• W2945640033 countsByYear W29456400332023 @default.
• W2945640033 crossrefType "journal-article" @default.
• W2945640033 hasAuthorship W2945640033A5000218370 @default.
• W2945640033 hasAuthorship W2945640033A5024136656 @default.
• W2945640033 hasAuthorship W2945640033A5027889441 @default.
• W2945640033 hasAuthorship W2945640033A5051915095 @default.
• W2945640033 hasAuthorship W2945640033A5077536735 @default.
• W2945640033 hasConcept C104317684 @default.
• W2945640033 hasConcept C126322002 @default.
• W2945640033 hasConcept C2776905138 @default.
• W2945640033 hasConcept C2776968632 @default.
• W2945640033 hasConcept C2777499651 @default.
• W2945640033 hasConcept C2777637488 @default.
• W2945640033 hasConcept C2778243283 @default.
• W2945640033 hasConcept C2778719061 @default.
• W2945640033 hasConcept C2779454058 @default.
• W2945640033 hasConcept C2779708577 @default.
• W2945640033 hasConcept C2781288988 @default.
• W2945640033 hasConcept C501593827 @default.
• W2945640033 hasConcept C523546767 @default.
• W2945640033 hasConcept C54355233 @default.
• W2945640033 hasConcept C547475151 @default.
• W2945640033 hasConcept C55493867 @default.
• W2945640033 hasConcept C64778159 @default.
• W2945640033 hasConcept C71924100 @default.
• W2945640033 hasConcept C86803240 @default.
• W2945640033 hasConcept C89423630 @default.
• W2945640033 hasConcept C90924648 @default.
• W2945640033 hasConceptScore W2945640033C104317684 @default.
• W2945640033 hasConceptScore W2945640033C126322002 @default.
• W2945640033 hasConceptScore W2945640033C2776905138 @default.
• W2945640033 hasConceptScore W2945640033C2776968632 @default.
• W2945640033 hasConceptScore W2945640033C2777499651 @default.
• W2945640033 hasConceptScore W2945640033C2777637488 @default.
• W2945640033 hasConceptScore W2945640033C2778243283 @default.
• W2945640033 hasConceptScore W2945640033C2778719061 @default.
• W2945640033 hasConceptScore W2945640033C2779454058 @default.
• W2945640033 hasConceptScore W2945640033C2779708577 @default.
• W2945640033 hasConceptScore W2945640033C2781288988 @default.
• W2945640033 hasConceptScore W2945640033C501593827 @default.
• W2945640033 hasConceptScore W2945640033C523546767 @default.
• W2945640033 hasConceptScore W2945640033C54355233 @default.
• W2945640033 hasConceptScore W2945640033C547475151 @default.
• W2945640033 hasConceptScore W2945640033C55493867 @default.
• W2945640033 hasConceptScore W2945640033C64778159 @default.
• W2945640033 hasConceptScore W2945640033C71924100 @default.
• W2945640033 hasConceptScore W2945640033C86803240 @default.
• W2945640033 hasConceptScore W2945640033C89423630 @default.
• W2945640033 hasConceptScore W2945640033C90924648 @default.

• next